Form 4: Lilly Endowment Inc. Sells Shares of Eli Lilly & Co (LLY)
SEC Filing
Lilly Endowment Inc., a 10% owner of Eli Lilly & Co, reports selling shares in multiple transactions on February 13, 2025.
Summary
- Lilly Endowment Inc., a significant shareholder of Eli Lilly & Co (LLY), filed a Form 4 with the SEC.
- The filing reports the sale of Eli Lilly & Co common stock on February 13, 2025.
- A total of 35,461 shares were sold in multiple transactions at weighted average prices ranging from $877.471 to $883.447.
- Following these transactions, Lilly Endowment Inc. still beneficially owns 96,646,532 shares of Eli Lilly & Co common stock.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing reporting a sale of shares. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.
Industry Context
Form 4 filings are a routine part of insider trading activity and provide transparency into the buying and selling activities of significant shareholders and company insiders. This sale by Lilly Endowment Inc. could be for portfolio rebalancing or other investment strategies.
Stakeholder Impact
- The sale of shares by a major shareholder like Lilly Endowment Inc. could potentially create short-term selling pressure on Eli Lilly & Co's stock price.
- However, the large remaining stake suggests continued confidence in the company's long-term prospects.
Key Dates
| Date | Description |
|---|---|
| 02/13/2025 | Date of the reported transactions (sale of shares). |
| 02/14/2025 | Date of the signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.